On July 7, Moderna fell 5.04% in regular trading, trading at approximately $79.38/share, with turnover of $2.16 billion. The decline was triggered by Bank of America raising its price target on Moderna to $38 from $34 while maintaining an Underperform rating, implying over 50% downside from the current stock price.

The $38 target also stands significantly below the FactSet consensus target of $50.53. Notably, Moderna had surged more than 18% the prior week, driven by its seasonal flu vaccine candidate mRNA-1010 receiving unanimous 9-0 support from an FDA advisory committee, with a final regulatory decision expected by August 5. Additional catalysts included Arete raising its target to $433 and the company unveiling its autoimmune CAR-T program mRNA-6007 at a recent science day event.

Following the sharp rally, the explicitly bearish institutional stance combined with profit-taking pressure served as a direct trigger for the pullback. The mixed analyst sentiment — ranging from Leerink Partners at $24 to Arete at $433 — reflects deep market disagreement over Moderna's platform transition and long-term valuation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)